EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sacubitril-Valsartan Lowers Blood Pressure in Patients on Dialysis: A Randomized Controlled Multicenter Study

Li Lin, Weijing Bian, Qun Luo, Liang Wang, Na Liu, Min Yang, Jun Cen, Kedan Cai, Jia Hua, Hongwei Gu, Hualin Qi, Zhihong Wang und 8 weitere

Kidney Diseases · 15.03.2025 · 11 (1) · 206-217

DOI: 10.1159/000545195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney Diseases, online erschienen am 15.03.2025. Verfasst von Li Lin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Individuals with end-stage kidney disease frequently grapple with uncontrolled hypertension, which elevates their risk for cardiovascular complications.

Methods

This randomized, controlled, multicenter study, conducted across 10 hospitals, aimed to compare the effectiveness and safety of sacubitril-valsartan versus irbesartan in managing hypertension among dialysis patients. The primary efficacy variable of the present study was the reduction in office blood pressure (BP) after 12 months of treatment. Participants were randomly allocated to receive either sacubitril-valsartan (angiotensin receptor-neprilysin inhibitor [ARNI]) or irbesartan (angiotensin receptor blocker [ARB]) treatment over a 12-month period. We gauged treatment efficacy through office and 24-h ambulatory BP readings, as well as serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP). Safety outcomes were also evaluated.

Results

Baseline office BP averaged 150/82 mm Hg and median NT-proBNP was 6,336 pg/mL. In the intention-to-treat analysis, office systolic BP reduction was significantly greater in the ARNI than ARB group (−10.4 vs. −4.6 mm Hg, p = 0.003) after adjustment for baseline BP. In hemodialysis (HD) patients, the mean systolic/diastolic BP reduction was also greater in the ARNI than ARB group (−15.9/2.4 vs. −6.6/1.1 mm Hg, p < 0.05). While for peritoneal dialysis (PD) patients, there were no significant between-group differences (p = 0.087). Per-protocol analyses in 215 patients on office BP and 137 patients on 24-h BP produced similar results. During the study period, there was no between-group difference in the overall incidence of fatal and nonfatal events and hyperkalemia.

Conclusion

In dialysis patients with hypertension, especially those undergoing HD, ARNI demonstrated superior effectiveness in reducing BP compared to ARB. The safety profiles of both treatments were comparable and acceptable.

Schlagwörter

Stichwörter der Autor:innen

Angiotensin receptor-neprilysin inhibitorClinical trialDialysis patientsHypertensionSacubitril-valsartan

Autor:innen und Institutionen

  • Department of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Nephrology, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.
  • Department of Nephrology, Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
  • Department of Nephrology, People's Hospital of Wuxi City, Wuxi, China.
  • Department of Nephrology, Oriental Hospital of Tongji University, Shanghai, China.
  • Department of Nephrology, Shanghai Construction Group Hospital, Shanghai, China.

Zitieren

APA

Lin, L., Bian, W., Luo, Q., Wang, L., Liu, N., Yang, M., Cen, J., Cai, K., Hua, J., Gu, H., Qi, H., Wang, Z., Niu, J., Chen, Y., Gu, Y., Hu, C., Li, S., Li, Y., Chen, N., & Li, X. (2025). Sacubitril-Valsartan Lowers Blood Pressure in Patients on Dialysis: A Randomized Controlled Multicenter Study. Kidney Diseases, 11(1), 206-217. https://doi.org/10.1159/000545195

Vancouver

Lin L, Bian W, Luo Q, Wang L, Liu N, Yang M, et al. Sacubitril-Valsartan Lowers Blood Pressure in Patients on Dialysis: A Randomized Controlled Multicenter Study. Kidney Diseases. 2025;11(1):206-217. doi:10.1159/000545195

BibTeX
@article{Lin2025,
  author = {Lin, Li and Bian, Weijing and Luo, Qun and Wang, Liang and Liu, Na and Yang, Min and Cen, Jun and Cai, Kedan and Hua, Jia and Gu, Hongwei and Qi, Hualin and Wang, Zhihong and Niu, Jianying and Chen, Yu and Gu, Yizheng and Hu, Chun and Li, Suhua and Li, Yan and Chen, Nan and Li, Xiao},
  title = {Sacubitril-Valsartan Lowers Blood Pressure in Patients on Dialysis: A Randomized Controlled Multicenter Study},
  journal = {Kidney Diseases},
  year = {2025},
  volume = {11},
  number = {1},
  pages = {206--217},
  doi = {10.1159/000545195}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche